BACKGROUND The programmed cell death protein 1 inhibitor pembrolizumab has become a key treatment for various cancers,including triple-negative breast cancer.However,it is associated with immune-related adverse events...BACKGROUND The programmed cell death protein 1 inhibitor pembrolizumab has become a key treatment for various cancers,including triple-negative breast cancer.However,it is associated with immune-related adverse events,including rare but serious neurological complications such as Guillain-Barrésyndrome(GBS).GBS is a potentially life-threatening autoimmune disorder characterized by muscle weakness and paralysis.We present a unique case of pembrolizumab-induced GBS to highlight the importance of recognizing this complication and managing it promptly in patients receiving immune checkpoint inhibitors.CASE SUMMARY A 69-year-old woman with a medical history of hypertension,anxiety,depression,and stage IIIB triple-negative breast cancer treated with pembrolizumab,carboplatin,and paclitaxel,presented to the emergency department with a 1-month history of tingling,lower extremity weakness,and shooting pain.Symptoms progressed to global weakness,ascending paralysis,and double vision.Neurological examination revealed significant lower extremity weakness and sensory deficits.Magnetic resonance imaging of the lumbar spine and cerebrospinal fluid analysis confirmed GBS.Initial treatment with intravenous immunoglobulin led to relapse,requiring additional intravenous immunoglobulin and high-dose glucocorticoids.The patient’s condition improved,pembrolizumab therapy was permanently discontinued,and she was discharged to a rehabilitation facility.CONCLUSION Pembrolizumab can induce GBS,necessitating early recognition,prompt diagnosis,and multidisciplinary management to prevent serious complications.展开更多
Cardiovascular problems have become the predominant cause of death worldwide and a rise in the number of patients has been observed lately.Currently,electrocardiogram(ECG)data is analyzed by medical experts to determi...Cardiovascular problems have become the predominant cause of death worldwide and a rise in the number of patients has been observed lately.Currently,electrocardiogram(ECG)data is analyzed by medical experts to determine the cardiac abnormality,which is time-consuming.In addition,the diagnosis requires experienced medical experts and is error-prone.However,automated identification of cardiovascular disease using ECGs is a challenging problem and state-of-the-art performance has been attained by complex deep learning architectures.This study proposes a simple multilayer perceptron(MLP)model for heart disease prediction to reduce computational complexity.ECG dataset containing averaged signals with window size 10 is used as an input.Several competing deep learning and machine learning models are used for comparison.K-fold cross-validation is used to validate the results.Experimental outcomes reveal that the MLP-based architecture can produce better outcomes than existing approaches with a 94.40%accuracy score.The findings of this study show that the proposed system achieves high performance indicating that it has the potential for deployment in a real-world,practical medical environment.展开更多
文摘BACKGROUND The programmed cell death protein 1 inhibitor pembrolizumab has become a key treatment for various cancers,including triple-negative breast cancer.However,it is associated with immune-related adverse events,including rare but serious neurological complications such as Guillain-Barrésyndrome(GBS).GBS is a potentially life-threatening autoimmune disorder characterized by muscle weakness and paralysis.We present a unique case of pembrolizumab-induced GBS to highlight the importance of recognizing this complication and managing it promptly in patients receiving immune checkpoint inhibitors.CASE SUMMARY A 69-year-old woman with a medical history of hypertension,anxiety,depression,and stage IIIB triple-negative breast cancer treated with pembrolizumab,carboplatin,and paclitaxel,presented to the emergency department with a 1-month history of tingling,lower extremity weakness,and shooting pain.Symptoms progressed to global weakness,ascending paralysis,and double vision.Neurological examination revealed significant lower extremity weakness and sensory deficits.Magnetic resonance imaging of the lumbar spine and cerebrospinal fluid analysis confirmed GBS.Initial treatment with intravenous immunoglobulin led to relapse,requiring additional intravenous immunoglobulin and high-dose glucocorticoids.The patient’s condition improved,pembrolizumab therapy was permanently discontinued,and she was discharged to a rehabilitation facility.CONCLUSION Pembrolizumab can induce GBS,necessitating early recognition,prompt diagnosis,and multidisciplinary management to prevent serious complications.
文摘Cardiovascular problems have become the predominant cause of death worldwide and a rise in the number of patients has been observed lately.Currently,electrocardiogram(ECG)data is analyzed by medical experts to determine the cardiac abnormality,which is time-consuming.In addition,the diagnosis requires experienced medical experts and is error-prone.However,automated identification of cardiovascular disease using ECGs is a challenging problem and state-of-the-art performance has been attained by complex deep learning architectures.This study proposes a simple multilayer perceptron(MLP)model for heart disease prediction to reduce computational complexity.ECG dataset containing averaged signals with window size 10 is used as an input.Several competing deep learning and machine learning models are used for comparison.K-fold cross-validation is used to validate the results.Experimental outcomes reveal that the MLP-based architecture can produce better outcomes than existing approaches with a 94.40%accuracy score.The findings of this study show that the proposed system achieves high performance indicating that it has the potential for deployment in a real-world,practical medical environment.
